The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice
Open accessAbstract
Activation of hepatic stellate cells in response to chronic inflammation represents a crucial step in the development of liver fibrosis. However, the molecules involved in the interaction between immune cells and stellate cells remain obscure. Herein, we identify the chemokine CCL5 (also known as RANTES), which is induced in murine and human liver after injury, as a central mediator of this interaction. First, we showed in patients with liver fibrosis that CCL5 haplotypes and intrahepatic CCL5 mRNA expression were associated with severe liver fibrosis. Consistent with this, we detected Ccl5 mRNA and CCL5 protein in 2 mouse models of liver fibrosis, induced by either injection of carbon tetrachloride (CCl4) or feeding on a methionine and choline-deficient (MCD) diet. In these models, Ccl5-/- mice exhibited decreased hepatic fibrosis, with reduced stellate cell activation and immune cell infiltration. Transplantation of Ccl5-deficient bone marrow into WT recipients attenuated liver fibrosis, identifying infiltrating hematopoietic cells as the main source of Ccl5. We then showed that treatment with the CCL5 receptor antagonist Met-CCL5 inhibited cultured stellate cell migration, proliferation, and chemokine and collagen secretion. Importantly, in vivo administration of Met-CCL5 greatly ameliorated liver fibrosis in mice and was able to accelerate fibrosis regression. Our results define a successful therapeutic approach to reduce experimental liver fibrosis by antagonizing Ccl5 receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
A second generation human haplotype map of over 3.1 million SNPs
The International HapMap Consortium (2007) · Nature · doi:10.1038/nature06258 · Cited by 4,438
A Comparison of Bayesian Methods for Haplotype Reconstruction from Population Genotype Data
Stephens, M., & Donnelly, P. (2003) · The American Journal of Human Genetics · doi:10.1086/379378 · Cited by 3,513
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649
Bataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866
Wu, H., Ghosh, S., Perrard, X. D., Feng, L., Garcia, G. E., Perrard, J. L., Sweeney, J. F., Peterson, L. E., Chan, L., Smith, C. W., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.638379 · Cited by 680
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Hepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
Roles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Remmerie, A., Martens, L., Thoné, T., Castoldi, A., Seurinck, R., Pavie, B., Roels, J., Vanneste, B., De Prijck, S., Vanhockerhout, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.004 · Cited by 592
Evolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 595
Krenkel, O., Puengel, T., Govaere, O., Abdallah, A. T., Mossanen, J. C., Kohlhepp, M., Liepelt, A., Lefebvre, E., Luedde, T., Hellerbrand, C., et al. (2018) · Hepatology · doi:10.1002/hep.29544 · Cited by 557
Self-citationThe Role of Chemokines in Wound Healing
Ridiandries, A., Tan, J. T. M., & Bursill, C. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103217 · Cited by 475
Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut
Seki, E., & Schnabl, B. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.219691 · Cited by 442
Mieli-Vergani, G., Vergani, D., Czaja, A. J., Manns, M. P., Krawitt, E. L., Vierling, J. M., Lohse, A. W., & Montano-Loza, A. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.17 · Cited by 425
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Targeting CCL5 in inflammation
Marques, R. E., Guabiraba, R., Russo, R. C., & Teixeira, M. M. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.837886 · Cited by 384
Role of cytokines and chemokines in non-alcoholic fatty liver disease
Braunersreuther, V. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i8.727 · Cited by 362
Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundThe Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Fujii, H., Kawada, N., & Japan Study Group of NAFLD (JSG-NAFLD) (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113863 · Cited by 299
Functional Role of Monocytes and Macrophages for the Inflammatory Response in Acute Liver Injury
Zimmermann, H. W., Trautwein, C., & Tacke, F. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00056 · Cited by 262
Self-citationLi, M., Sun, X., Zhao, J., Xia, L., Li, J., Xu, M., Wang, B., Guo, H., Yu, C., Gao, Y., et al. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0279-0 · Cited by 225
Hendrikx, T., Porsch, F., Kiss, M. G., Rajcic, D., Papac-Miličević, N., Hoebinger, C., Goederle, L., Hladik, A., Shaw, L. E., Horstmann, H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.004 · Cited by 220
Luci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195
Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis
Hu, M., Wang, Y., Liu, Z., Yu, Z., Guan, K., Liu, M., Wang, M., Tan, J., & Huang, L. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00836-6 · Cited by 136
Functional role of chemokines in liver disease models
Sahin, H., Trautwein, C., & Wasmuth, H. E. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.168 · Cited by 107
Self-citationAre mast cells instrumental for fibrotic diseases?
Overed-Sayer, C., Rapley, L., Mustelin, T., & Clarke, D. L. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00174 · Cited by 105
Spatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis
Chung, B. K., Øgaard, J., Reims, H. M., Karlsen, T. H., & Melum, E. (2022) · Hepatology Communications · doi:10.1002/hep4.2001 · Cited by 85
Ni, Y., Zhuge, F., Ni, L., Nagata, N., Yamashita, T., Mukaida, N., Kaneko, S., Ota, T., & Nagashimada, M. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155272 · Cited by 86
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
Galastri, S., Zamara, E., Milani, S., Novo, E., Provenzano, A., Delogu, W., Vizzutti, F., Sutti, S., Locatelli, I., Navari, N., et al. (2012) · Clinical Science · doi:10.1042/cs20110515 · Cited by 62
Lefere, S., Devisscher, L., & Tacke, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1718106 · Cited by 47
Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis
Morikawa, R., Nakamoto, N., Amiya, T., Chu, P.-S., Koda, Y., Teratani, T., Suzuki, T., Kurebayashi, Y., Ueno, A., Taniki, N., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.033 · Cited by 40
Platelet Factor 4 Attenuates Experimental Acute Liver Injury in Mice
Drescher, H. K., Brandt, E. F., Fischer, P., Dreschers, S., Schwendener, R. A., Kowalska, M. A., Canbay, A., Wasmuth, H. E., Weiskirchen, R., Trautwein, C., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00326 · Cited by 17
Self-citation
Metadata
- Authors
- Berres, M.-L., Koenen, R. R., Rueland, A., Zaldivar, M. M., Heinrichs, D., Sahin, H., Schmitz, P., Streetz, K. L., Berg, T., Gassler, N., Weiskirchen, R., Proudfoot, A., Weber, C., Trautwein, C., & Wasmuth, H. E.
- Venue
- Journal of Clinical Investigation
- Published
- 2010-11-01
- Volume
- 120
- Issue
- 11
- Pages
- 4129-4140
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2136547076
- Cited by
- 263
- References
- 41
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.